AVDL Avadel Pharmaceuticals plc

5.76
-0.16  -3%
Previous Close 5.92
Open 5.92
Price To Book -8
Market Cap 215,713,728
Shares 37,450,300
Volume 267,481
Short Ratio
Av. Daily Volume 420,091
Stock charts supplied by TradingView

NewsSee all news

  1. Avadel Pharmaceuticals Announces Key Appointments to Leadership Team To Support Continued Transformation and the Advancement of FT218

    - - -Thomas S. McHugh appointed as Chief Financial Officer- - -Dr. Jason Vaughn appointed Senior Vice President of Technical Operations DUBLIN, Ireland, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals

  2. Avadel Pharmaceuticals Achieves Enrollment Target in REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

    205 patients enrolled; additional patients currently in screening will be allowed to enroll if eligible Topline data from the REST-ON study expected in Q2 2020 DUBLIN, Ireland, Nov. 25, 2019 (GLOBE NEWSWIRE) --

  3. Avadel Pharmaceuticals to Present at Two Upcoming Investor Conferences

    DUBLIN, Ireland, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating

  4. Avadel Pharmaceuticals Reports Third Quarter 2019 Financial Results and Raises Revenue Guidance for FY2019

    Enrollment currently at 200 patients for the pivotal REST-ON Phase 3 study (97.5% complete); the Company currently expects to complete patient enrollment by end of 2019, with data readout expected in Q2 2020 Revenue of

  5. Avadel Announces Resignation of Kevin Kotler from Board of Directors

    DUBLIN, Ireland, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on developing FT218, a once-nightly formulation of sodium oxybate, for narcolepsy, today announced that

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved June 3, 2013.
Bloxiverz (neostigmine methylsulfate)
Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery
Announced approval May 2 2016
Akovaz
Hypotension
Phase 3 data due 2Q 2020.
FT 218
Excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy
Approved June 30 2014.
VAZCULEP (phenylephrine hydrochloride)
Clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia
Approved Jun 3 2013
Bloxiverz (neostigmine methylsulfate)
Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery
PDUFA date extended by three months to December 15, 2019.
AV001
Hospital product

Latest News

  1. Avadel Pharmaceuticals Announces Key Appointments to Leadership Team To Support Continued Transformation and the Advancement of FT218

    - - -Thomas S. McHugh appointed as Chief Financial Officer- - -Dr. Jason Vaughn appointed Senior Vice President of Technical Operations DUBLIN, Ireland, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals

  2. Avadel Pharmaceuticals Achieves Enrollment Target in REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

    205 patients enrolled; additional patients currently in screening will be allowed to enroll if eligible Topline data from the REST-ON study expected in Q2 2020 DUBLIN, Ireland, Nov. 25, 2019 (GLOBE NEWSWIRE) --

  3. Avadel Pharmaceuticals to Present at Two Upcoming Investor Conferences

    DUBLIN, Ireland, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating

  4. Avadel Pharmaceuticals Reports Third Quarter 2019 Financial Results and Raises Revenue Guidance for FY2019

    Enrollment currently at 200 patients for the pivotal REST-ON Phase 3 study (97.5% complete); the Company currently expects to complete patient enrollment by end of 2019, with data readout expected in Q2 2020 Revenue of

  5. Avadel Announces Resignation of Kevin Kotler from Board of Directors

    DUBLIN, Ireland, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on developing FT218, a once-nightly formulation of sodium oxybate, for narcolepsy, today announced that

  6. Avadel Pharmaceuticals Announces Pharmacokinetic (PK) Data for Once-Nightly FT218 that will be Included in an Oral Presentation at the World Sleep 2019 Congress on September 25th

    DUBLIN, Ireland, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, for narcolepsy, today

  7. Avadel Pharmaceuticals Announces FDA Agreement to Reduce the Sample Size for the Ongoing Pivotal Phase 3 Study for Once-Nightly FT218; Full Enrollment Now Expected by End of 2019

    FDA agrees with Company's proposed changes to the statistical analysis plan for the REST-ON Phase 3 study for once-nightly sodium oxybate, FT218Reduces estimated time to completion by up to 12 months; now expected to

  8. Velan Launches Consent Solicitation to Reconstitute the Progenics Board With Its Five Highly-Qualified, Independent Director Nominees

    Believes its Five Completely Independent Nominees Would Bring Much-Needed Skill Sets and Drastically Improve the Board's Strategic Oversight and Corporate Governance Failings Expresses Disappointment with Current

  9. Avadel Pharmaceuticals Announces an Oral Presentation on Investigational Once-Nightly Sodium Oxybate (FT218) at the World Sleep 2019 Congress on September 25th

    DUBLIN, Ireland, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on developing FT218 for narcolepsy, today announced that Dr. Michael Thorpy, Director of the Sleep-Wake

  10. Avadel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24th

    DUBLIN, Ireland, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on developing FT218, a once-nightly formulation of sodium oxybate, for narcolepsy, today announced that